The Week Ahead: Fed...
Health Care: Drugs
Exact Sciences Corporation (EXAS: NASDAQ)
$9.55 -0.10 | -1.04%
06/04/12 - 12:25 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.39 | 0.58 | 0.98 |
| Price to Sales (TTM) | 132.58 | 4.62 | 1.42 |
| Price to Book (MRQ) | 7.27 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 7.27 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -14.30 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -15.40 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -0.40 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -22.10 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 51.60 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 10.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 11.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.01 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.01 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 13.10 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 21.20 | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -649.66 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -8.40 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -39.70 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -29.60 | 2.20 | 2.50 |
| Return on Investment (TTM) | -45.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -40.30 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 68,180.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -572,902.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with EXAS
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- Contributor8 Health Care Stocks With R...
- Usergdean1
- Userradforj John's SEP & Ta...
- UserBlind Rookie
- Userbbrads Portfolio 1
- Userremodelit Portfolio 1
- UserGoBears Under $5 Stock Picks
- UserMornan
- Userjwpao Portfolio 1
Latest EXAS Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- Look to Exact Sciences, Not Radient Pharma, for Best Colon Cancer Screen Test 01.23.12 | 01:01 pm
- Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- Exact Sciences Corporation (EXAS): CORRECTION 10.06.11 | 04:10 pm
- Exact Sciences' Colon Cancer Screening Trial 07.12.11 | 08:07 am
- 8 Health Care Stocks With Recent Gains 06.29.11 | 02:06 pm
- Biotech Stock Mailbag: Neoprobe 05.06.11 | 07:05 am
- Radient Pharma Readies Onko-Sure Data 03.29.11 | 02:03 pm
- Mayo Clinic Denies Test Link to Radient Pharma 03.07.11 | 05:03 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
Press Releases for EXAS
- Exact Sciences To Participate In June Investor Conferences - Business Wire 05.30.12 | 10:05 am
- Exact Sciences Extends, Expands Relationship With Mayo Clinic - Business Wire 05.17.12 | 09:05 am
- Exact Sciences To Participate In May Investor Conferences - Business Wire 05.07.12 | 11:05 am
- Exact Sciences Reports First-Quarter 2012 Financial Results - Business Wire 05.01.12 | 07:05 am
- Exact Sciences To Host First-Quarter 2012 Results Webcast And Call - Business Wire 04.23.12 | 02:04 pm
- Exact Sciences’ Executives, Colon Cancer Challenge Leaders To Ring Nasdaq Opening Bell - Business Wire 03.19.12 | 09:03 am
- Exact Sciences To Participate In March Investor Conferences - Business Wire 02.29.12 | 11:02 am
- Exact Sciences Reports Fourth-Quarter, Full-Year 2011 Financial Results - Business Wire 02.23.12 | 07:02 am
- Exact Sciences Announces Appointment Of Stoltenberg As Chief Commercial Officer - Business Wire 02.20.12 | 04:02 pm
- Exact Sciences Promotes Arora To Chief Operating Officer - Business Wire 02.16.12 | 04:02 pm
Partner Headlines for EXAS
- UPDATE: Auriga Raises PT to $13 on EXACT Sciences - Benzinga 02.24.12 | 04:02 pm
- Exact Sciences Promotes Arora to Chief Operating Officer - Benzinga 02.16.12 | 04:02 pm
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- Momentum Ideas: Friday's High Volume Gainers Chased by Big Money Managers - Seeking Alpha 04.17.11 | 07:04 am
- Cramer's Mad Money - 6 Earnings and IPOs to Watch for the Coming Week (4/8/11) - Seeking Alpha 04.10.11 | 04:04 am
- Life Science Portfolios: Reflecting on a Year of Out-Performance - Seeking Alpha 12.29.10 | 05:12 am
- UPDATE1-New colon cancer test works without colonoscopy - Reuters 10.28.10 | 05:10 pm
- Detecting More Upside Potential for EXACT Sciences - Seeking Alpha 10.22.10 | 09:10 pm
- Piper Jaffray’s Top Picks for The Second Half of 2010 (CPHD, EXAS, GNMK) - Benzinga 08.24.10 | 09:08 am
- 6 Ways to Trade FDA and Clinical Trial News - Seeking Alpha 05.28.10 | 02:05 pm
